Molecular testing to enhance the response of colorectal cancers (CRC) to targeted and conventional therapies has been the center of many recent studies. While testing for KRAS mutations is generally accepted as a requirement to select patients for anti-EGFR antibody therapies, guidelines for other markers have not been evaluated. The objective of the guideline is to establish evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR directed therapies and conventional chemotherapy regimens.
Four professional societies: American Society of Clinical Pathologists (ASCP), College of American Pathologists (CAP), the Association for Molecular Pathology (AMP) and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline on the use of molecular marker testing for patients with early and advanced colorectal cancer. This evidence‐based clinical practice guideline will help establish standard molecular marker testing, guide targeted therapy decisions, and advance personalized care for these patients.
This session will present the evidence-based recommendations for the molecular testing guideline for colorectal cancer.
- Describe current guideline recommendations for molecular testing in the evaluation of colorectal cancer to determine prognosis and prediction of response to therapies.
- Understand recommended laboratory practice guideline for the use and performance of molecular testing in the evaluation of colorectal cancer to determine prognosis and prediction of response to therapies.
- Apply recommendations for molecular biomarker testing for colorectal cancer.
Antonia R. Sepulveda, MD, PhD, FCAP